Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab plus Nivolumab in NSCLC with Bone Metastases
NCT03669523Phase 2Completed
- Sponsor
- Centre Hospitalier Annecy Genevois
- Start
- Nov 2018
- Primary completion
- Oct 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denosumab in non-small cell lung cancer (NSCLC), sponsored by Centre Hospitalier Annecy Genevois. Primary endpoint: Overall Response Rate in patients with PD-L1 expression >= 1% at 24 months. Started Nov 2018; status: completed.
02
Drugs
denosumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03669523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669523.